D/E 0.01 — least levered decile in Healthcare (≈10th pctile)
P/E22.5xB+
P/E 22.5 — below the Healthcare median (≈40th pctile)
PEG0.59A-
PEG 0.59 — strong; Lynch's preferred zone
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 90.2
Quality0.90
Growth0.93
Value0.88
Why this score
Durable high returns
Entry · Margin of safety
52-week rangeNear 52-week low
71% off the 12-month high
vs DCF fair value14% belowest. fair value ~$25
Quality signals · context only
Gross profitability51% · Agross profit ÷ total assets (Novy-Marx)
ROIC17.9% · A-return on invested capital — not score-weighted
Why now
Doximity's digital platform, deeply embedded in medical professionals' workflows with tools like Ask and Scribe, generates exceptional cash flow and profitability. With a $326m free cash flow against a $4.0b market cap and a 30.4% profit margin, the company is a highly efficient compounder. A compelling 0.59 PEG ratio further underscores its undervaluation, suggesting significant upside as its network effect continues to drive engagement and revenue growth.
Moat
Doximity's durable edge is built on a powerful network effect among U.S. medical professionals, who rely on its personalized newsfeed and HIPAA-compliant workflow tools for clinical content and peer interaction. This deep integration into daily practice creates substantial switching costs, reinforced by the company's impressive 20.6% Return on Equity, indicative of pricing power derived from its dominant position in health information services.
Risk
The primary bear case for Doximity centers on a potential deceleration in its core growth drivers, as evidenced by the latest 13.1% FY YoY revenue growth, which may signal increasing market saturation or competitive pressures for sponsored content from pharmaceutical manufacturers and health systems. Despite a negligible 0.01 debt-to-equity ratio, if revenue growth continues to slow, the current 22.5 P/E multiple could appear elevated, confirming the bear thesis if future quarterly reports fail to reaccelerate top-line expansion.
Horizon
1-3 yr $24.53 (19-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $30.96 at ~7% CAGR — dividend + buyback compounding. 10 yr $39.71 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · DOCS
$
%
%
Shares to buy
90
Position size
$1,981
4.0% of portfolio
Stop price
$16.51
25% below $22.01
$ at risk if stopped
$495.23
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Doximity, Inc. (DOCS): score, valuation & FAQ
Doximity, Inc. (DOCS) is a Health Information Services company that scores 90.2 out of 100 on the Bull Rankings quality-growth model — an exceptional reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are D/E (A), PEG (A-) and Rev (B+). On valuation, DOCS sits about 14% below our discounted-cash-flow fair value (a margin of safety).
Is DOCS a good stock to buy?
Bull Rankings scores DOCS 90.2 out of 100 on its quality-growth model, which is an exceptional reading. That is driven by D/E (A), PEG (A-) and Rev (B+). A score is a quantitative screen of Doximity, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does DOCS score 90.2 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). DOCS earns its highest marks on D/E (A), PEG (A-) and Rev (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is DOCS overvalued or undervalued?
Based on $22.01, DOCS sits about 14% below our discounted-cash-flow fair value (a margin of safety). It trades at a 22.5x× P/E (graded B+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in DOCS?
The primary bear case for Doximity centers on a potential deceleration in its core growth drivers, as evidenced by the latest 13.1% FY YoY revenue growth, which may signal increasing market saturation or competitive pressures for sponsored content from pharmaceutical manufacturers and health systems. Despite a negligible 0.01 debt-to-equity ratio, if revenue growth continues to slow, the current 22.5 P/E multiple could appear elevated, confirming the bear thesis if future quarterly reports fail to reaccelerate top-line expansion.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.